Hypoxia-induced Tumor Heterogeneity and Immune Evasion

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia’s role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.

• Hypoxia-Driven Immune Escape: Molecular PathwaysHypoxia in Tumour Microenvironment (TME) of Solid Tumours Promotes Tumour Heterogeneity, Immune Suppression, Immune Evasion and Mechanisms of Therapeutic ResistanceHypoxia-Mediated Immune Evasion Mechanisms in Solid Tumors – Focus on Renal, Pancreatic, Head and Neck, Breast, and Non-Small Cell Lung CancersHypoxia-centered Tumor Ecology: Linking Immunity, Intercellular Communication, and Cellular PlasticityHypoxic Niches and Microbiome Dynamics: From Oxygen Deprivation to Functional MetabotypesHypoxia-driven mitochondrial remodeling as a source of tumor metabolic heterogeneity and immune escapeTumor hypoxia, immune evasion, and therapeutic opportunitiesVessel Normalization Mechanisms to Treat Hypoxia-dependent Diseases: The Immunocompetent Microenvironment ChallengeTumour Hypoxia and Response to RadiotherapyThe role of hypoxia in immune heterogeneity of glioblastomaHypoxia gene signatures in cancer: development, biological insights, and clinical translationHypoxia-Driven Cancer Progression: Clinical Interventions and Emerging Therapeutic ParadigmsExploiting Tumor Hypoxia: CP-506 at the Forefront of Hypoxia-Activated Prodrug DevelopmentFuture Perspectives and Challenges in Hypoxia, Tumor Heterogeneity, and Immune Resistance